Introduction {#s1}
============

Cryptorchidism (CO), or undescended testis, affects approximately 3% of all male live births, making it one of the most common congenital disorders. Despite a high rate of spontaneous resolution during the first year of life, CO is firmly established as the primary risk factor for subsequent development of testicular germ cell tumors (TCGT) (John Radcliffe Hospital Study Group, [@B29]; Berkowitz et al., [@B3]; Thong et al., [@B66]; Paulozzi, [@B47]). TGCT are the most common form of malignancy among young men in the United States. Advances in systemic therapy have improved overall TGCT survival from 83% in 1975--1979 to 96% in 1999--2005 (Jemal et al., [@B28]). However, incidence of TGCT has nearly doubled during the same time period ([@B56]), and it is now evident that significant sequelae include subfertility, (Walsh et al., [@B73]) sexual dysfunction, (Magelssen et al., [@B33]) and elevated risk of second malignancy (Moller et al., [@B38]; Fossa et al., [@B15]; Travis et al., [@B68]; Van den Belt-Dusebout et al., [@B71]). Therefore, a clear understanding of etiologic risk factors and more comprehensive risk stratification is a priority of TGCT research.

Risk of CO and TGCT are associated with additional disorders of the male reproductive system, hypospadias, and impaired spermatogenesis. This pattern is postulated to reflect origins of all of these conditions in errors of development of the fetal testis according to the testicular dysgenesis syndrome hypothesis, which elegantly accounts for experimental research identifying genetic and early environmental factors predisposing to these phenotypes in animal models (Skakkebæk et al., [@B58]). Little is currently known regarding the specific insults that may lead to elevated risk of individual and joint phenotypes in humans, or the stages of testicular development when such factors may act. In the present report we comprehensively reviewed the rich set of published observational data on co-occurrence of CO and TGCT as a first step in disentangling the complex associations among these related conditions.

Currently, little is known about the overall characterization of tumor risk in patients with a prior history of CO. Individual estimates of relative risk from the literature range from 1.35 (95% *CI* = 0.73--2.48) to 18 (95% *CI* = 12--26), (Miller and Seljelik, [@B35]; Mostofi, [@B42]; Morrison, [@B40]; Henderson et al., [@B22]; Loughlin et al., [@B32]; Schottenfeld et al., [@B55]; Wobbes et al., [@B76]; Fonger et al., [@B14]; Coldman et al., [@B7]; Depue et al., [@B10]; Mills et al., [@B36]; Pottern et al., [@B50]; Moss et al., [@B41]; Giwercman et al., [@B18]; Swerdlow et al., [@B65], [@B64]; Gershman and Stolley, [@B17]; Strader et al., [@B61]; Thornhill et al., [@B67]; Haughey et al., [@B21]; Benson et al., [@B2]; Stone et al., [@B60]; United Kingdom Testicular Cancer Study Group (UK), [@B70]; Gallagher et al., [@B16]; Davies et al., [@B9]; Moller et al., [@B39]; Prener et al., [@B51]; Petridou et al., [@B48]; Sabroe and Olsen, [@B54]; Sigurdson et al., [@B57]; Weir et al., [@B75]; Stang et al., [@B59]; Bonner et al., [@B5]; Herrinton et al., [@B23]; Dieckmann and Pichlmeier, [@B12]; Kanto et al., [@B30]; Hardell et al., [@B20]; McGlynn et al., [@B34]; Myrup et al., [@B43]; Pettersson et al., [@B49]; Walschaerts et al., [@B72]; Dusek et al., [@B13]) suggesting significant differences in study design and/or heterogeneity of the effects of clinical characteristics which may impact risk of TGCT amongst males with CO. Potential modifying factors include anatomic location (abdominal vs. inguinal vs. ectopic) and laterality (unilateral vs. bilateral) of undescended testes, age at treatment, mode of treatment (spontaneous descent vs. hormones or orchiopexy), as well as temporal trends in TGCT risk, and tumor histology. Previous meta-analyses evaluating the CO-TGCT association have been limited to specific subsets of these factors (Castejon Casado et al., [@B6]; Walsh et al., [@B74]; Tuazon et al., [@B69]; Akre et al., [@B1]). We report a broader systematic review and meta-analysis of the overall association between CO-TGCT, and explore the possible impact of study design, temporal trends, and clinical features on this association.

Materials and methods {#s2}
=====================

The analysis followed specifications for meta-analysis of observational studies in epidemiology (Stroup et al., [@B62]) and adhere to PRISMA guidelines (Moher et al., [@B37]). The outcome was TGCT. The exposure was CO, defined as a testicle undescended at birth that subsequently descended spontaneously, was repositioned into the scrotum by orchiopexy or hormone therapy, or remained undescended. Subgroups were defined by features of study design, CO, and TGCT.

Study selection
---------------

We searched the MEDLINE (National Library of Medicine, Bethesda, MD, USA) Pubmed interface without language restrictions for human studies published through December 2011, using key words "CO," "undescended testicle," "undescended testis," "undescended testes," "case-control study," "cohort study" in combination with "testicular cancer," "testicular carcinoma," "testicular neoplasia," "testis cancer," "testis carcinoma," "testis neoplasia," reviewing also reports cited in retrieved articles and review articles, and by citation indices (ISI Web of Science) for these reports. We also sought high-quality unpublished data. The Review Protocol has not been registered.

Data extraction and coding
--------------------------

A genetic counselor and a statistician reviewed retrieved articles to determine eligibility for the meta-analysis, resolving conflicts by consensus among themselves and an epidemiologist. Data on study design, overall CO-TGCT associations, and subgroup-specific CO-TGCT associations were extracted systematically by a single reviewer and confirmed by two others. We eliminated redundant data arising from repeated publication, consulting original authors whenever possible.

We extracted published information on RRs relating CO to TGCT as follows: when provided, we recorded point estimates of the odds ratio (OR) for case-control studies and standardized incidence ratio (SIR) for cohort studies, with corresponding standard error or information from which it could be calculated (variance, *CI*, *p*-value). When only a point estimate was reported, we requested corresponding variance term from original authors. If the OR estimate was not provided, we calculated it from published tabular data.

### Features of study design

We noted the following features of each study: data structure (case-control study of TGCT, cohort study of males born with CO, TGCT cases for whom frequency of CO was compared to external population), country where study was conducted, race/ethnicity of participants, and source of CO data (birth record, medical record before TGCT diagnosis, medical record at/following TGCT diagnosis, reported by participant and/or his mother). For case-control and cohort studies we noted source of reference group (population or population-based registry, hospital or neighborhood, friend). We distinguished published RR estimates extracted from those we calculated from published data; for published estimates, we tabulated covariates and matching variables in original analyses.

### Features of cryptorchidism

When possible we extracted or calculated RR estimates of CO-TGCT association for subgroups defined by each of several features of CO: laterality of undescended testicle relative to TGCT (unilateral CO contralateral to tumor, unilateral CO with relation to tumor unspecified, unilateral CO ipsilateral to tumor, bilateral CO), level of maldescent (ectopic, inguinal, abdominal), whether definition of CO included spontaneous descent, means of resolving CO (spontaneous, orchiopexy or hormone therapy, remained undescended), and age at resolution. For this variable we used frequently published categories (0--9 years of age, 10--14 years, 10 years or older, 15 years or older) (United Kingdom Testicular Cancer Study Group (UK), [@B70]; Moller et al., [@B39]; Swerdlow et al., [@B64]) combining data from smaller intervals if provided (Swerdlow et al., [@B64]). Among studies with alternate cut points, one provided raw data from which we recalculated estimates within above strata (Herrinton et al., [@B23]); for four others (Pottern et al., [@B50]; Strader et al., [@B61]; Myrup et al., [@B43]; Pettersson et al., [@B49]) we assigned data to closest category corresponding to above strata (**Table S3**, footnotes b--d).

### Features of testicular germ cell tumors

We extracted or calculated RR estimates for subgroups defined by histology (non-seminoma, non-seminoma/mixed germ cell tumor (GCT), mixed GCT, seminoma). A separate code for mixed GCT was introduced in 1990 (ICD-0-2), and tumors of mixed histology were previously coded as non-seminoma. Therefore, for studies including diagnoses before 1990, if authors did not specify that non-seminoma excluded mixed histology, we coded reported non-seminoma as "non-seminoma/mixed GCT." As a measure of year of TGCT diagnosis, we determined midpoint of range of years of diagnosis among cases participating in each study.

### Unpublished data

Original population-based case-control data (Lacson et al., [@B30a]) were provided before publication. Briefly, 163 TGCT cases identified by the Los Angeles County Cancer Surveillance Program (CSP) and 284 age-matched neighborhood controls were enrolled. TGCT data (histologic type, laterality, age at diagnosis) were provided by the CSP, and CO data (laterality, age at resolution, mean of resolution) were provided by participants and their mothers during in-person interviews.

Statistical analyses
--------------------

### Estimating overall and stratum-specific summary RR of CO-TGCT association

We conducted all meta-analyses using a random effects model, which accounts for between- and within-study variance thereby incorporating the conservative assumption that individual studies estimate different effect sizes (Sutton et al., [@B63]). We used STATA 8.0 (Stata Corp, College Station, TX) to weight natural log of each contributing OR or SIR estimate by the reciprocal of the corresponding variance. We used this technique to estimate overall and stratum-specific summary relative risk (sRR) estimates. Forest plots were graphed displaying each study\'s contribution to sRRs.

Meta-analyses were performed separately for case-control (**Tables S2--S4**, columns A) and cohort (**Tables S2--S4**, columns B) studies, with summary measures subsequently pooled. Resulting sRR estimates \[Figures [1A](#F1){ref-type="fig"}, [2A](#F2){ref-type="fig"}--[C](#F2){ref-type="fig"} and [3A](#F3){ref-type="fig"}--[C](#F3){ref-type="fig"}; **Tables S2--S4**, columns C (boldface)\] summarize available data on CO-TGCT associations from studies with reference groups judged comparable to cases. Other articles compared CO prevalence of TGCT cases with CO prevalence from external populations, rather than source population of the cases; limited comparability in such studies is now recognized as a potential source of severe bias (Rothman et al., [@B53a]). We therefore summarized these data separately (Figure [1C](#F1){ref-type="fig"}; **Tables S2--S4**, column D).

![**Forest and funnel plots for overall association of testicular germ cell tumor (TGCT) risk with history of cryptorchidism (A) Forest plot for combined cohort and case-control data; (B) Funnel plot for combined cohort and case-control data; (C) Forest plot for TGCT case series data; (D) Funnel plot for TGCT case series data**.](fendo-03-00182-g0001){#F1}

![**Forest plots of relative risk estimates relating cryptorchidism to risk of TGCT, stratified by features of cryptorchidism; (A) By laterality of cryptorchidism relative to tumor; (B) By method whereby cryptorchidism was resolved; (C) By age at treatment for cryptorchidism**.](fendo-03-00182-g0002){#F2}

![**Forest plots of relative risk estimates relating cryptorchidism to risk of TGCT, stratified by features of TGCT; (A) By histologic type of tumor; (B) By year of TGCT diagnosis (midpoint for study); (C) By histologic type of tumor and year of TGCT diagnosis (midpoint for study)**. ^1^Mixed; ^2^Non-Seminoma; ^3^Non-seminoma+Mixed.](fendo-03-00182-g0003){#F3}

We implemented Egger\'s test of publication bias, assessed heterogeneity by appropriate *p*-value and I^2^ (Berkowitz et al., [@B3]) estimates, and assessed trends as described in Appendix Methods, along with procedures for imputation and sensitivity analysis.

Role of the funding source
--------------------------

Sponsors had no role in the design, implementation, or reporting of the research. Drs. Victoria K. Cortessis and Leslie Bernstein had full access to all of the original data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Results {#s3}
=======

We identified 147 published articles reporting on both CO and TGCT in humans, eliminating those that did not provide data relating CO to TGCT risk (*N* = 95, not cited), or were duplicate reports of data included in the analysis (10 reports, **Table S1**). Data from 35 of the remaining 42 reports and raw data from one unpublished case-control study contributed to meta-analyses on which we base our inferences (Table [1A](#T1){ref-type="table"}; **Figure S1**). We requested from authors of three of these reports (Moss et al., [@B41]; Strader et al., [@B61]; Swerdlow et al., [@B65]) standard error data corresponding to published histology stratum-specific point estimates, and received these for one (Strader et al., [@B61]). In all, data on 9542 TGCT cases contributed to the analyses. For historical interest, we separately summarized estimates from the remaining seven reports, whose authors compared CO among TGCT case-series with frequencies of CO measured outside source populations of the cases (Table [1B](#T1){ref-type="table"}).

###### 

**Epidemiologic studies of cryptorchidism and testicular germ cell tumors (TGCT) included in the meta-analysis**.

  **First author**                                                                                                                        **Year published**   **Country**      **Ethnicity[^a^](#TN1){ref-type="table-fn"}**   **Number of TGCT cases**   **Number of controls**   **Source of cases[^b^](#TN2){ref-type="table-fn"}**   **Source of controls[^b^](#TN2){ref-type="table-fn"}**   **Spontaneous descent included[^c^](#TN3){ref-type="table-fn"}**   **Number of variables matched and/or adjusted for**   **Source of cryptorchidism data[^d^](#TN4){ref-type="table-fn"}**
  --------------------------------------------------------------------------------------------------------------------------------------- -------------------- ---------------- ----------------------------------------------- -------------------------- ------------------------ ----------------------------------------------------- -------------------------------------------------------- ------------------------------------------------------------------ ----------------------------------------------------- -------------------------------------------------------------------
  **A. STUDIES THAT PROVIDED DATA ON TGCT CASES AND COMPARABLE REFERENCE GROUP**                                                                                                                                                                                                                                                                                                                                                                                                                                            
  ***i. Case-control studies***                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  Morrison (Morrison, [@B40])                                                                                                             1976                 USA              NS                                              596                        602                      Reg                                                   Pop                                                      No                                                                 0                                                     TCMR
  Henderson (Henderson et al., [@B22])                                                                                                    1979                 USA              WP                                              79                         79                       Reg                                                   Neigh                                                    NS                                                                 2                                                     M
  Loughlin (Loughlin et al., [@B32])                                                                                                      1980                 USA              WO                                              24                         35                       Hosp                                                  Hosp                                                     No                                                                 2                                                     C + M
  Schottenfold (Schottenfeld et al., [@B55])                                                                                              1980                 USA              WO                                              157                        309                      Hosp                                                  Hosp + Neigh                                             NS                                                                 3                                                     C + M
  Coldman (Coldman et al., [@B7])                                                                                                         1982                 Canada           NS                                              93                         79                       Hosp                                                  Hosp                                                     Yes                                                                2                                                     C, TCMR
  Depue (Depue et al., [@B10])                                                                                                            1983                 USA              WO                                              107                        108                      Reg                                                   Neigh                                                    NS                                                                 2                                                     C
  Mills (Mills et al., [@B36])                                                                                                            1984                 USA              WP                                              347                        347                      Hosp                                                  Hosp                                                     NS                                                                 3                                                     TCMR
  Pottern (Pottern et al., [@B50])                                                                                                        1985                 USA              WP                                              271                        259                      Hosp                                                  Hosp                                                     Yes                                                                2                                                     C + M
  Moss (Moss et al., [@B41])                                                                                                              1986                 USA              WP                                              246                        252                      Reg + Hosp                                            Friends                                                  NS                                                                 3                                                     C, M
  Swerdlow (Swerdlow et al., [@B65])                                                                                                      1987                 England          NS                                              259                        489                      Reg + Hosp                                            Hosp                                                     Yes                                                                2                                                     C
  Gershman (Gershman and Stolley, [@B17])                                                                                                 1988                 USA              NS                                              79                         79                       Reg                                                   Pop                                                      NS                                                                 2                                                     C
  Strader (Strader et al., [@B61])                                                                                                        1988                 USA              WO                                              326                        675                      Reg                                                   Pop                                                      No                                                                 1                                                     C
  Haughey (Haughey et al., [@B21])                                                                                                        1989                 USA              WO                                              247                        247                      Reg                                                   Neigh                                                    NS                                                                 2                                                     C
  UK (United Kingdom Testicular Cancer Study Group (UK), [@B70])                                                                          1994                 UK               WO                                              794                        794                      Reg + Hosp                                            Pop                                                      No                                                                 1                                                     C + M
  Gallagher (Gallagher et al., [@B16])                                                                                                    1995                 Canada           WP                                              506                        994                      Reg                                                   Pop                                                      NS                                                                 1                                                     C
  Prener (Prener et al., [@B51])                                                                                                          1996                 Denmark          NS                                              171                        366                      Reg                                                   Pop                                                      Yes                                                                4                                                     PTCMR
  Davies (Davies et al., [@B9])                                                                                                           1996                 England          NS                                              129                        395                      Reg                                                   Pop + Reg                                                NS                                                                 6                                                     C + M
  Møller (Moller et al., [@B39])                                                                                                          1996                 Denmark          NS                                              514                        720                      Reg                                                   Pop                                                      Yes                                                                1                                                     C
  Petridou (Petridou et al., [@B48])                                                                                                      1997                 Greece           NS                                              97                         198                      Hosp                                                  Pop                                                      NS                                                                 2                                                     C + M
  Sabroe (Sabroe and Olsen, [@B54])                                                                                                       1998                 Denmark          NS                                              357                        704                      Reg                                                   Pop                                                      Yes                                                                2                                                     BR
  Sigurdson (Sigurdson et al., [@B57])                                                                                                    1999                 USA              WP                                              160                        136                      Hosp                                                  Friends                                                  NS                                                                 4                                                     C
  Weir (Weir et al., [@B75])                                                                                                              2000                 Canada           NS                                              325                        490                      Reg                                                   Pop                                                      No                                                                 5                                                     C
  Stang (Stang et al., [@B59])                                                                                                            2001                 Germany          NS                                              262                        797                      Reg                                                   Pop                                                      Yes                                                                2                                                     C, M
  Bonner (Bonner et al., [@B5])                                                                                                           2002                 USA              WO                                              116                        328                      Hosp                                                  Hosp                                                     NS                                                                 1                                                     C
  Herrinton (Herrinton et al., [@B23])                                                                                                    2003                 USA              WP                                              183                        551                      Hosp                                                  Hosp                                                     Yes                                                                2                                                     PTCMR
  Dieckmann (Dieckmann and Pichlmeier, [@B12])                                                                                            2004                 Unknown          Unknown                                         538                        551                      Unknown                                               Unknown                                                  Unknown                                                            Unknown                                               Unknown
  Hardell (Hardell et al., [@B20])                                                                                                        2007                 Sweden           NS                                              888                        870                      Reg                                                   Pop                                                      NS                                                                 1                                                     C
  McGlynn (McGlynn et al., [@B34])                                                                                                        2007                 USA              WP                                              767                        928                      Reg                                                   Pop                                                      NS                                                                 3                                                     C
  Walschaerts (Walschaerts et al., [@B72])                                                                                                2007                 France           NS                                              200                        585                      Hosp                                                  Hosp                                                     NS                                                                 1                                                     C
  Dusek (Dusek et al., [@B13])                                                                                                            2008                 Czech Republic   WO                                              356                        317                      Hosp                                                  Hosp + Neigh                                             NS                                                                 1                                                     C
  Lacson (Lacson et al., [@B30a])                                                                                                                              USA              WP                                              163                        284                      Reg                                                   Neigh                                                    Yes                                                                3                                                     C
  ***ii. Cohort studies of boys with Cryptorchidism***                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Giwercman (Giwercman et al., [@B18])                                                                                                    1987                 Denmark          NS                                              6                          --                       Hosp                                                  --                                                       No                                                                 2                                                     PTCMR
  Benson (Benson et al., [@B2])                                                                                                           1991                 USA              NS                                              2                          --                       Hosp                                                  --                                                       Yes                                                                1                                                     PTCMR
  Swerdlow (Swerdlow et al., [@B64])                                                                                                      1997                 England          NS                                              11                         --                       Hosp                                                  --                                                       No                                                                 2                                                     PTCMR
  Pettersson (Pettersson et al., [@B49])                                                                                                  2007                 Sweden           NS                                              56                         --                       Reg                                                   --                                                       No                                                                 2                                                     PTCMR
  Myrup (Myrup et al., [@B43])                                                                                                            2007                 Denmark          NS                                              110                        --                       Reg                                                   --                                                       No                                                                 2                                                     PTCMR
  **B. STUDIES THAT PROVIDED DATA ON TGCT CASE SERIES, ESTIMATING RISK RATIOS USING CRYPTORCHIDISM FREQUENCY FROM EXTERNAL POPULATION**                                                                                                                                                                                                                                                                                                                                                                                     
  Miller (Miller and Seljelik, [@B35])                                                                                                    1971                 Norway           NS                                              314                        --                       Reg                                                   --                                                       NS                                                                 --                                                    TCMR
  Mostofi (Mostofi, [@B42])                                                                                                               1973                 USA              NS                                              2000                       --                       Army Reg                                              --                                                       NS                                                                 --                                                    TCMR
  Wobbes (Wobbes et al., [@B76])                                                                                                          1980                 Netherlands      NS                                              230                        --                       Hosp                                                  --                                                       No                                                                 --                                                    TCMR
  Fonger (Fonger et al., [@B14])                                                                                                          1981                 Canada           NS                                              646                        --                       Hosp                                                  --                                                       Yes                                                                --                                                    TCMR
  Thornhill (Thornhill et al., [@B67])                                                                                                    1988                 Ireland          NS                                              240                        --                       Reg                                                   --                                                       NS                                                                 --                                                    TCMR
  Stone (Stone et al., [@B60])                                                                                                            1991                 Australia        NS                                              778                        --                       Hosp                                                  --                                                       Yes                                                                --                                                    TCMR
  Kanto (Kanto et al., [@B30])                                                                                                            2004                 Japan            J                                               240                        --                       Hosp                                                  --                                                       Yes                                                                --                                                    TCMR

*NS, not specified; WO, white only; WP, white plus other ethnicities; J, Japanese*.

*Reg, cancer registry; Hosp, hospital; Neigh, neighborhood; Pop, population*.

*NS, not specified*.

*C, case/control self report; M, case/control mother\'s report; C + M, case/control self report supplemented by mother\'s report; BR, birth record; PTCMR, pre-testicular cancer medical record, TCMR: testicular cancer medical record*.

Sensitivity analyses revealed that no single case-control or cohort study influenced either overall or stratum-specific estimates of RR sufficiently to alter interpretation (results not shown). Egger\'s tests revealed no evidence of publication bias among cohort data (*p* = 0.68), case-control data (*p* = 0.34), or these data types combined (*p* = 0.40); however, addition of data from the TGCT case series introduced an impression of substantial publication bias (*p* = 0.01). Visual inspection of Begg\'s funnel plots showed that while magnitude and standard error of RR estimates from most cohort and case-control studies (34 of 36) are within the 95% confidence limits (Figure [1B](#F1){ref-type="fig"}), this is true of a far smaller proportion of TGCT case-series (4 of 7, Figure [1D](#F1){ref-type="fig"}).

Overall CO-TGCT association and effects of study design
-------------------------------------------------------

We estimated sRR of developing TGCT following a history of CO to be 4.0(95% *CI* = 3.4--4.6) in case-control studies (**Table S2Ai**) and 4.8(95% *CI* = 3.2--7.2) in cohort studies (**Table S2Bi**). The sRR estimated by pooling these results was 4.1(95% *CI* = 3.6--4.7), with 14% of the variance (I^2^) attributed to between-study heterogeneity (Figures [1A,B](#F1){ref-type="fig"}; Table **S2Ci**). By contrast, sRR estimated from studies that compared CO frequencies between TGCT case series and external populations was 14.8(95% *CI* = 10.7--20.4), with 86% of variance attributed to between-study heterogeneity (Figures [1C,D](#F1){ref-type="fig"}; **Table S2Di**).

Two additional features of study design appeared to modify sRR estimated among case-control and cohort studies: time CO was recorded, and inclusion of spontaneous descent in CO definition. The RR estimate was notably greater, 9.9(95% *CI* = 3.5--28.2), in the single study (Mills et al., [@B36]) that determined CO history from medical record entries made around the time of TGCT diagnosis, and substantially lower, 1.3(95% *CI* = 0.7--2.5), in the single study (Sabroe and Olsen, [@B54]) in which CO had been recorded at birth. This latter study was likely the only one to have included in the CO group a large proportion of men whose testes would have descended in the first months of life. The same study appeared to be largely responsible for modification by whether definition of CO included spontaneous descent (*p*~heterogeneity~ = 0.002 for analysis including this study, *p*~heterogeneity~ = 0.57 for analysis excluding it, **Table S2Cvi**). Accordingly, this study was a clear outlier in the funnel plot (Figure [1B](#F1){ref-type="fig"}), while all others fell very near or within the 95% confidence limits.

Modification by features of cryptorchidism
------------------------------------------

Several features of CO appeared to modify the CO-TGCT association (Figure [2](#F2){ref-type="fig"}; **Table S3**). Analyses stratified on laterality of undescended testes relative to TGCT revealed an apparent trend: sRR estimates increased steadily in progression from TGCT arising in testes contralateral to unilateral CO \[sRR = 1.5(95% *CI* = 0.9--2.6)\], on unspecified side relative to unilateral CO \[sRR = 3.5(95% *CI* = 2.7--4.7)\], ipsilateral to unilateral CO \[sRR = 5.4(95% *CI* = 3.7--7.8)\], and in either testis following bilateral CO \[sRR = 9.8(95% *CI* = 6.2--15.7)\] (Figure [2A](#F2){ref-type="fig"}; **Table S3Ci**). Data on anatomic location of undescended testes, provided for no case-control study and only one cohort study (Swerdlow et al., [@B64]), were insufficient to determine whether TGCT risk differs appreciably following abdominal vs. inguinal non-descent (**Table S3Cii**). Therefore, the meta-analysis did not confirm the report from a single TGCT case series (Stone et al., [@B60]) of far higher RR following abdominal non-descent (**Table S3Dii**).

In analyses stratified on means of resolving CO, estimates increased in the progression of testes that descended spontaneously \[sRR = 1.3(95% *CI* = 0.9--1.8)\], testes repositioned by surgery or hormone therapy \[sRR = 4.7(95% *CI* = 3.7--6.1)\], and testes remaining undescended \[sRR = 6.2(95% *CI* = 3.7--10.4)\] (Figure [2B](#F2){ref-type="fig"}; **Table S3Ciii**). Analyses stratified on both means of resolution and age at resolution suggested greater RR among those with older age at spontaneous descent or therapeutic resolution, although estimates for those who experienced spontaneous descent did not achieve statistical significance (Figure [2C](#F2){ref-type="fig"} and **Table S3Civ**).

Modification by features of TGCT
--------------------------------

Analyses relating CO to tumor histology were conducted first in a subset of data excluding three studies that reported "no difference" in RR of seminoma vs. non-seminoma without providing stratum-specific estimates. The results hinted that RR of seminoma may exceed that of non-seminoma (**Table S4Ci**). To minimize the possibility that systematic omission of data from studies reporting no difference had spuriously created this impression, we repeated this analysis using a fuller set of data that included values imputed for those studies; these results also suggested a stronger association of CO with seminoma (Figure [3A](#F3){ref-type="fig"}; **Table S4Cii**).

Analyses within strata defined by year of TGCT diagnosis suggest that magnitude of the CO-TGCT association diminished steadily from the 1950\'s forward. Highest sRR, 6.8(95% *CI* = 4.2--10.9), was estimated among studies with midpoint year of TGCT diagnosis in the 1950\'s, and lowest, 3.6(95% *CI* = 3.1--4.1), in studies with midpoint 1990 or later (*p*~trend~\< 0.001; Figure [3B](#F3){ref-type="fig"}; **Table S4Ciii**). Further stratification on histology, possible only for 1960\'s forward, revealed that this decrease results largely from a dramatic decrease in the CO-seminoma association \[sRR = 9.3(95% *CI* = 4.0--21.8) for 1960--1969, sRR = 3.4(95% *CI* = 2.5--4.5) for 1990+; *p*~trend~ = 0.009), in contrast to no clear trend for other histologies (*p*~trend~= 0.320) (Figure [3C](#F3){ref-type="fig"}; **Table S4Civ**).

Trends in occurrence of individual conditions
---------------------------------------------

Analyses of frequency of CO among controls participating in the case-control studies, (Morrison, [@B40]; Henderson et al., [@B22]; Loughlin et al., [@B32]; Schottenfeld et al., [@B55]; Coldman et al., [@B7]; Depue et al., [@B10]; Mills et al., [@B36]; Pottern et al., [@B50]; Moss et al., [@B41]; Swerdlow et al., [@B65]; Gershman and Stolley, [@B17]; Strader et al., [@B61]; Haughey et al., [@B21]; United Kingdom Testicular Cancer Study Group (UK), [@B70]; Gallagher et al., [@B16]; Davies et al., [@B9]; Moller et al., [@B39]; Prener et al., [@B51]; Petridou et al., [@B48]; Sabroe and Olsen, [@B54]; Weir et al., [@B75]; Stang et al., [@B59]; Bonner et al., [@B5]; Herrinton et al., [@B23]; Dieckmann and Pichlmeier, [@B12]; Hardell et al., [@B20]; McGlynn et al., [@B34]; Walschaerts et al., [@B72]; Dusek et al., [@B13]; Lacson et al., [@B30a]) for which midpoint TGCT diagnosis years ranged from 1960\'s through 1990+, revealed no evidence that CO became more common among TGCT-free men during this period (*p*~trend~ = 0.295, data not shown).

Separate analyses of SEER 9 incidence data revealed that while annual age-standardized incidence of non-seminoma/mixed GCT increased over 28% (from 1.8 to 2.3 new diagnoses per 100,000) from 1973--1978 to 1994--1998, the increase in seminoma was far greater, 68% (from 2.2 to 3.7 per 100,000) during the same interval (**Figure S2**).

Discussion {#s4}
==========

Meta-analysis of data from case-control and cohort studies suggests that young men with a history of CO experience approximately 4-fold increased risk of TGCT. Estimates from TGCT case-series whose frequency of CO was compared with separate populations were regarded as unreliable; this practice may cause severe bias (Rothman et al., [@B53a]), which may account for the far larger sRR and between-study variation estimated from these reports.

Addressing more subtle differences in study design, we found that sRR estimates from case-control and cohort studies were notably modified by methods used to determine a man\'s history of CO. The stronger association estimated in the single case-control study in which history of CO was determined from medical record notes made at TGCT diagnosis may have arisen from better recall of CO among cases than controls, since CO was a recognized TGCT risk factor when these diagnoses were made. Such recall bias may have contributed, also, to large effects reported for case series, because history of CO was similarly determined in all of these studies. Undescended testes that descended spontaneously in infancy would rarely be recorded in medical records after the neonatal period, or recalled by study participants or their mothers. We therefore anticipate that only the single study in which CO was recorded at birth (Sabroe and Olsen, [@B54]) would have identified a high proportion of men with this history. Weak CO-TGCT association reported in this study may indicate that boys born with CO whose testes descend spontaneously in early months experience TGCT risk approaching that of the general population. This possibility has implications for both managing CO and understanding origins of TGCT, so we hope that it will be explored further in retrospective cohorts for which there are detailed neonatal records.

The apparent modification of sRR by features of CO and TGCT may provide insight regarding TGCT etiology. Two general explanations for the CO-TGCT association have long been offered. The *common cause hypothesis* attributes the association to one or more unidentified etiologic factors shared by CO and TGCT, whereas the *position hypothesis* asserts that suprascrotal environment increases malignant potential of undescended testes. Hussman suggested two testable predictions of the position hypothesis (Husmann, [@B25]): (1) in unilateral CO, fully descended contralateral testes should not experience elevated TGCT risk, and (2) early orchiopexy should decrease TGCT risk. Regarding the first, we estimated a lesser sRR for contralateral testes \[1.5(95% *CI* = 0.9--2.6)\] than for ipsilateral testes \[5.4(95% *CI* = 3.7--7.8)\], suggesting a deleterious effect of suprascrotal position. Also consistent with positional effects, sRR among those with bilateral non-descent \[9.8(95% *CI* =6.2--15.7)\] was, within statistical precision of the meta-analysis, indistinguishable from twice sRR of those with unilateral non-descent \[2×sRR~ipsilateral~ = 10.8(7.4--15.6)\]. However, published data are insufficient (24 cases in 7 studies) to rule out a small increase in risk to contralateral testes (e.g., 20%), as would be required to strictly affirm Hussman\'s first prediction. We note, however, that some true increase in risk to contralateral testes would not necessarily rule out the position hypothesis, because central responses to a single testis in a suprascotal position could, in theory, contribute to malignant potential of the contralateral testis. For example, in rodent models of unilateral CO created surgically, degenerative changes (Quinn, [@B52]; Zakaria et al., [@B77]) and altered gene expression (Iizuka et al., [@B27]) were demonstrated in contralateral, descended testes. A phenomenon observed in humans is also consistent with this possibility: among patients with unilateral TGCT who undergo biopsy of the contralateral testis, men with a history of CO are more often found to have the presumptive TGCT precursor carcinoma *in situ* testis/intra-tubular germ cell neoplasia than those without history of CO (Dieckmann and Loy, [@B11]). Regarding Hussman\'s second prediction, we observed greater TGCT risk among those who experienced later resolution. However, we cannot confidently conclude that deleterious effects of suprascrotal position are responsible. An alternate explanation, which we cannot rule out, is that men with earlier resolution of CO experienced as a group inherently lower risk of TGCT. This might occur, for example, if this group included a higher proportion of boys destined to experience spontaneous descent if therapeutic intervention had been delayed. Because elevated risk was observed, regardless of age at orchiopexy, the clinical significance of available data is that patients undergoing orchiopexy at any age should be closely monitored; thus along with their parents or primary care givers and primary care physicians, they should be made aware of the increased risk.

Unfortunately, published data could not distinguish between risks experienced by men with histories of abdominal vs. inguinal non-descent. These distinct phenotypes may provide a means of determining relevance to human CO and TGCT of animal models of CO with high (Hsieh-Li et al., [@B24]; Rijli et al., [@B53]; Good et al., [@B19]; Nef and Parada, [@B44]; Overbeek et al., [@B46]) or low (Hutson, [@B26]; Lahoud et al., [@B31]) non-descent resulting from disruption of specific genes. If found to be relevant to human CO and TGCT, these models may become valuable tools in TGCT research, which has long suffered from absence of animal models of common forms of TGCT (Oosterhuis and Looijenga, [@B45]). Therefore, documenting position of undescended testes before orchiopexy may be useful for future research and in follow-up of men with a history of CO, particularly in the era of electronic medical records.

Modification by features of TGCT may suggest etiologic heterogeneity of these tumors.

Morrison ([@B40]) apparently first suggested that CO is more strongly associated with seminoma than non-seminoma, although subsequent reports were inconsistent. The meta-analysis suggested greater RR for seminoma than for non-seminoma, and an intermediate value for mixed GCT, by addressing a far larger set of data than any single study and treating mixed GCT as a distinct histologic type. Although mechanisms underlying this pattern remain unknown, this finding suggests that tumors of distinct histologic types may have separate etiologies and/or result from events at different developmental stages. This possibility accords with the far more dramatic decreases in the CO-seminoma association observed over time. This trend, together with the observation that incidence of seminoma has risen more rapidly than that of non-seminoma/mixed GCT (**Figure S2**), raises the intriguing possibility that increasing occurrence of seminoma may involve increasing exposure to unidentified environmental factors through processes unrelated to CO.

In conclusion, this meta-analysis provides a detailed quantitative summary of available high-quality observational data on the association between CO and TGCT, including observations that can no longer be made due to trends toward younger age at CO repair and increasing TGCT incidence. Results of subgroup analyses indicate possible future directions in understanding both stratification of TGCT risk among boys born with undescended testes and TGCT etiology. Meta analyses addressing features of CO suggest that while bilateral CO is associated with nearly twice the TGCT risk as unilateral CO, data are inadequate to assess the role of anatomic position of the undescended testis. Early repair is associated with lower TGCT risk, but published data do not provide a basis for recommending optimal time of repair or to determine whether optimal repair can reduce risk to baseline. Therefore, all CO patients and their families should be counseled to be aware of future risk. Additional data are needed to affirm the possibility that TGCT risk is not elevated among boys whose testes descend spontaneously after birth. Results of subgroup analyses addressing features of TGCT suggest multiple pathways to malignancy and indicate considerable heterogeneity in risk of TGCT following CO. Both possibilities warrant mechanistic examination using contemporary tools of molecular biology.
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